Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/npjpcrm.2014.3 http://scihub22266oqcxt.onion/10.1038/npjpcrm.2014.3 C4373257!4373257!24841833     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       NPJ+Prim+Care+Respir+Med 2014 ; 24 (ä): 14003- Nephropedia Template TP {{tp|p=24841833|t=2014. Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial |pdf=|usr=}}{{24841833}} gab.com Text Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial JO: NPJ Prim Care Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=24841833 #FOAvip Background:: The benefits of pharmacotherapy with tiotropium HandiHaler 18??g for patients with chronic obstructive pulmonary disease (COPD) have been previously demonstrated. However, few data exist regarding the treatment of moderate disease (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II). Aims:: To determine whether tiotropium improves lung function/patient-reported outcomes in patients with GOLD stage II COPD naive to maintenance therapy. Methods:: A randomised 24-week double-blind placebo-controlled trial of tiotropium 18??g once daily (via HandiHaler) was performed in maintenance therapy?naive patients with forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7 and post-bronchodilator FEV1 ?50 and <80%. Results:: A total of 457 patients were randomised (238 tiotropium, 219 placebo; mean age 62 years; FEV1 1.93?l (66% predicted)). Tiotropium was superior to placebo in mean change from baseline in post-dose FEV1 area under the curve from 0 to 3?h (AUC0?3h) at week 24 (primary endpoint): 0.19 vs. ?0.03?l (least-squares mean difference 0.23?l, P<0.001). FVC AUC0?3h, trough and peak FEV1 and FVC were significantly improved with tiotropium versus placebo (P<0.001). Compared with placebo, tiotropium provided numerical improvements in physical activity (P=NS). Physician?s Global Assessment (health status) improved (P=0.045) with less impairment on the Work Productivity and Activity Impairment questionnaire (P=0.043) at week 24. The incidence of exacerbations, cough, bronchitis and dyspnoea was lower with tiotropium than placebo. Conclusions:: Tiotropium improved lung function and patient-reported outcomes in maintenance therapy?naive patients with GOLD stage II COPD, suggesting benefits in initiating maintenance therapy early. Twit Text FOAVip Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial ????NPJ Prim Care Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=24841833 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24841833 #FOAvip English Wikipedia <ref>{{Cite pmid|24841833}}</ref> Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial #MMPMID24841833 Troosters T; Sciurba FC; Decramer M; Siafakas NM; Klioze SS; Sutradhar SC; Weisman IM; Yunis C NPJ Prim Care Respir Med 2014[]; 24 (ä): 14003- PMID24841833show ga Background:: The benefits of pharmacotherapy with tiotropium HandiHaler 18??g for patients with chronic obstructive pulmonary disease (COPD) have been previously demonstrated. However, few data exist regarding the treatment of moderate disease (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II). Aims:: To determine whether tiotropium improves lung function/patient-reported outcomes in patients with GOLD stage II COPD naive to maintenance therapy. Methods:: A randomised 24-week double-blind placebo-controlled trial of tiotropium 18??g once daily (via HandiHaler) was performed in maintenance therapy?naive patients with forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7 and post-bronchodilator FEV1 ?50 and <80%. Results:: A total of 457 patients were randomised (238 tiotropium, 219 placebo; mean age 62 years; FEV1 1.93?l (66% predicted)). Tiotropium was superior to placebo in mean change from baseline in post-dose FEV1 area under the curve from 0 to 3?h (AUC0?3h) at week 24 (primary endpoint): 0.19 vs. ?0.03?l (least-squares mean difference 0.23?l, P<0.001). FVC AUC0?3h, trough and peak FEV1 and FVC were significantly improved with tiotropium versus placebo (P<0.001). Compared with placebo, tiotropium provided numerical improvements in physical activity (P=NS). Physician?s Global Assessment (health status) improved (P=0.045) with less impairment on the Work Productivity and Activity Impairment questionnaire (P=0.043) at week 24. The incidence of exacerbations, cough, bronchitis and dyspnoea was lower with tiotropium than placebo. Conclusions:: Tiotropium improved lung function and patient-reported outcomes in maintenance therapy?naive patients with GOLD stage II COPD, suggesting benefits in initiating maintenance therapy early. äTiotropium in patients with moderate COPD naive to maintenance therapy(epmc).pdf DeepDyve Pubget Overpricing